Skip to main content

Table 1 Patient characteristics

From: The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study

Characteristic Number Percent
All Patients 66 100
Age (years) Median (min, max) 72 (57, 93)  
PSA (ng/ml)—Median (min, max) 31.5 (1.0,64.0)  
Ethnicity
 Non-White 9 13.6
 White 57 86.4
Body Mass Index
 Underweight (<18.5) 1 1.5
 Normal (18.5–24.9) 13 19.7
 Overweight (25.0–29.9) 25 37.9
 Obese 14 21.2
 Not Available 13 19.7
Diabetes
 No 62 93.9
 Yes 4 6.1
Performance Status
 PS 0 31 47.0
 PS1-2 35 53.0
Gleason score
 5–6 2 3.0
 7 11 16.7
 8–10 51 77.3
 Missing 2 3.0
Metastatic Volume
 Low 31 47.0
 High 35 53.0
Treatment Arm
 ADT 34 51.5
 ADT + Chemo 31 47.0
 Not Available 1 1.5
  1. ADT Androgen Deprivation Therapy, Chemo Chemotherapy